Therapy Areas: Central Nervous System
Acadia Pharmaceuticals Eyes USD 250m Raise from Stock Offering
24 September 2019 - - US-based biopharmaceutical company Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) plans to offer and sell, in an underwritten public offering and subject to market and other conditions, USD 250m of its common stock, the company said.

There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering. ACADIA intends to grant the underwriters a 30-day option to purchase up to an additional USD 37.5m of its common stock.

Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

The company has developed and commercialised the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Acadia also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome.
Login
Username:

Password: